

EC Certificate - Production Quality Assurance

Directive 93/42/EEC on Medical Devices, Annex V

No.

CE 563923

Issued To:

**Medical Brands Innovations B.V.
Piet Heinkade 199
Amsterdam
1019 HC
The Netherlands**

In respect of:

Manufacture of non-sterile wart and corn removal gel and cryotherapy device for treatment of warts

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex V. The quality assurance system meets the requirements of the directive. For the placing on the market of class IIb and class III products an Annex III certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):



Gary E Slack, Senior Vice President - Medical Devices

First Issued: **2010-12-01**

Date: **2020-07-03**

Expiry Date: **2024-05-26**

...making excellence a habit.™

Page 1 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.

This certificate was issued electronically and is bound by the conditions of the contract.


EC Certificate - Production Quality Assurance

Supplementary Information to CE 563923

Issued To:

Medical Brands Innovations B.V.
Piet Heinkade 199
Amsterdam
1019 HC
The Netherlands

| Number | Device Name | Intended Purpose per IFU |
|--------------------|---------------------|--------------------------|
| Class IIa | | |
| MD 0303 | Wart / Corn Removal | --- |
| MD 1402 MD 0303 | Cryo Wart Removal | --- |



First Issued: **2010-12-01**

Date: **2020-07-03**

Expiry Date: **2024-05-26**

...making excellence a habit.™

Page 2 of 2

Validity of this certificate is conditional on the quality system being maintained to the requirements of the Directive as demonstrated through the required surveillance activities of the Notified Body. This approval excludes all products designed and/or manufactured by a third party on behalf of the company named on this certificate, unless specifically agreed with BSI.
 This certificate was issued electronically and is bound by the conditions of the contract.

22 August 2023

Medical Brands Innovations B.V.
Weesperstraat, 114
1112 AP Diemen
The Netherlands

To whom it may concern,


The transitional provisions specified in MDR Article 120(3) prohibit Notified Bodies from issuing new certificates or amending, modifying, supplementing any existing MDD/AIMDD certificates from 26th May 2021.

This letter is to confirm that BSI has reviewed and approved the change(s) detailed in the table below. These changes do not represent a significant change in design or intended purpose under MDR Article 120(3) and as per the guidance provided in MDCG 2020-3. The related MDD certificate specified below remains valid until the expiry date specified on the certificate.

| Certificate | Directive and Annex | Reference Number | Changes approved |
|--------------------|----------------------------|-------------------------|--|
| CE 563923 | 93/42/EEC Annex V | 3835904 | Change of the legal manufacturer address to the following; Medical Brands Innovations B.V. Weesperstraat, 114 1112 AP Diemen The Netherlands |

Should you have any queries concerning your certification, or if we can be of further assistance to you, please contact your BSI Scheme Manager.

Yours sincerely,



Graeme Tunbridge
Senior Vice President, Medical Devices